中国科兴新冠疫苗智利Ⅲ期试验初步结果显示良好安全性和免疫原性

2021-04-03 尹南 张笑然 新华社

智利有关专家团队17日在圣地亚哥举行发布会,介绍了去年11月以来中国科兴公司新冠疫苗在智利进行Ⅲ期临床试验的初步情况,证实科兴疫苗具有良好的安全性和免疫原性。

智利有关专家团队17日在圣地亚哥举行发布会,介绍了去年11月以来中国科兴公司新冠疫苗在智利进行Ⅲ期临床试验的初步情况,证实科兴疫苗具有良好的安全性和免疫原性。

当天,智利天主教大学领导的科兴疫苗Ⅲ期临床试验团队向智利卫生部、科技部和公共卫生研究院提交了疫苗质量、安全性和免疫原性的相关报告。

在疫苗安全性方面,专家称,基于约500名志愿者参与的初步研究结果显示,无一例严重不良反应,最常见的不良反应为接种部位疼痛,通常较轻微且持续不超过一两天,头疼、低热等不良反应的比例低于5%,与安慰剂组比例相当。报告的结论是,科兴疫苗具有良好的安全性,接种者对该疫苗的耐受性好。

专家称,对于疫苗免疫原性研究显示,第一剂疫苗接种14天后可在部分接种者体内检测到新冠病毒抗体的增加,第二剂接种后2周,90%的接种者体内抗体明显增加,抗体具有中和能力,这意味着能够预防病毒入侵人体细胞。

专家还指出,科兴疫苗在60岁以上人群中和60岁以下人群中产生的免疫反应没有区别。

据悉,科兴疫苗智利Ⅲ期临床试验共招募了2000多名志愿者,在智利全国8个中心进行。除智利天主教大学外,当地还有多所公立、私立医院和大学参与了这项试验。智利公共卫生研究院于今年1月20日宣布给予科兴新冠疫苗紧急使用许可。

智利于今年2月3日启动全国新冠疫苗大规模接种。截至3月17日,智利已有527万人接种了至少一剂新冠疫苗,其中250万人完成两剂新冠疫苗接种。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1663196, encodeId=a0651663196b7, content=<a href='/topic/show?id=769995e97d' target=_blank style='color:#2F92EE;'>#Ⅲ期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9579, encryptionId=769995e97d, topicName=Ⅲ期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e21b25545293, createdName=Shirley Xuan, createdTime=Sat Jun 19 07:12:30 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393821, encodeId=8236139382106, content=<a href='/topic/show?id=718528982e3' target=_blank style='color:#2F92EE;'>#免疫原性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28982, encryptionId=718528982e3, topicName=免疫原性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Mon Apr 05 06:12:30 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029335, encodeId=070a1029335ad, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sat Apr 03 18:12:30 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953582, encodeId=78c09535828f, content=中国人没有什么办不到, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210403/5ff406be14214a2382446bee2a6a5a17/d86ca8b32a014802a07fb644f93b3a73.jpg, createdBy=90132272125, createdName=121a9258m18暂无昵称, createdTime=Sat Apr 03 17:37:37 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1663196, encodeId=a0651663196b7, content=<a href='/topic/show?id=769995e97d' target=_blank style='color:#2F92EE;'>#Ⅲ期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9579, encryptionId=769995e97d, topicName=Ⅲ期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e21b25545293, createdName=Shirley Xuan, createdTime=Sat Jun 19 07:12:30 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393821, encodeId=8236139382106, content=<a href='/topic/show?id=718528982e3' target=_blank style='color:#2F92EE;'>#免疫原性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28982, encryptionId=718528982e3, topicName=免疫原性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Mon Apr 05 06:12:30 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029335, encodeId=070a1029335ad, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sat Apr 03 18:12:30 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953582, encodeId=78c09535828f, content=中国人没有什么办不到, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210403/5ff406be14214a2382446bee2a6a5a17/d86ca8b32a014802a07fb644f93b3a73.jpg, createdBy=90132272125, createdName=121a9258m18暂无昵称, createdTime=Sat Apr 03 17:37:37 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1663196, encodeId=a0651663196b7, content=<a href='/topic/show?id=769995e97d' target=_blank style='color:#2F92EE;'>#Ⅲ期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9579, encryptionId=769995e97d, topicName=Ⅲ期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e21b25545293, createdName=Shirley Xuan, createdTime=Sat Jun 19 07:12:30 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393821, encodeId=8236139382106, content=<a href='/topic/show?id=718528982e3' target=_blank style='color:#2F92EE;'>#免疫原性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28982, encryptionId=718528982e3, topicName=免疫原性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Mon Apr 05 06:12:30 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029335, encodeId=070a1029335ad, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sat Apr 03 18:12:30 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953582, encodeId=78c09535828f, content=中国人没有什么办不到, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210403/5ff406be14214a2382446bee2a6a5a17/d86ca8b32a014802a07fb644f93b3a73.jpg, createdBy=90132272125, createdName=121a9258m18暂无昵称, createdTime=Sat Apr 03 17:37:37 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
    2021-04-03 公卫新人

    新冠肺炎,疫情何时才能消失

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1663196, encodeId=a0651663196b7, content=<a href='/topic/show?id=769995e97d' target=_blank style='color:#2F92EE;'>#Ⅲ期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9579, encryptionId=769995e97d, topicName=Ⅲ期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e21b25545293, createdName=Shirley Xuan, createdTime=Sat Jun 19 07:12:30 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393821, encodeId=8236139382106, content=<a href='/topic/show?id=718528982e3' target=_blank style='color:#2F92EE;'>#免疫原性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28982, encryptionId=718528982e3, topicName=免疫原性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Mon Apr 05 06:12:30 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029335, encodeId=070a1029335ad, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sat Apr 03 18:12:30 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953582, encodeId=78c09535828f, content=中国人没有什么办不到, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210403/5ff406be14214a2382446bee2a6a5a17/d86ca8b32a014802a07fb644f93b3a73.jpg, createdBy=90132272125, createdName=121a9258m18暂无昵称, createdTime=Sat Apr 03 17:37:37 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
    2021-04-03 121a9258m18暂无昵称

    中国人没有什么办不到

    0

相关资讯

JNNP:Erenumab对发作性偏头痛患者功能结果的影响

Erenumab是一种全人类单克隆抗体,可抑制典型降钙素基因相关肽(CGRP)受体。临床研究已证明Erenumab对发作性偏头痛(EM)和慢性偏头痛(CM)患者的疗效和安全性,包括先前预防性偏头痛治疗

Ann Rheum Dis:乌帕替尼治疗类风湿性关节炎的安全性

与阿达木单抗相比,乌帕替尼治疗的患者带状疱疹和CPK升高的风险增加。乌帕替尼、甲氨蝶呤或阿达木单抗治疗的患者恶性肿瘤、MACE和VTE的发生率相似。

TCT 2020|VOYAGER PAD研究:药物涂层装置在外周动脉血运重建中长期安全性得到认可

认可 对于有症状的外周动脉疾病(PAD)患者,腔内血运重建可有效改善症状及保肢率,但存在术后再狭窄的困扰。紫杉醇药物涂层装置(DCB)的设计初衷就是为了解决再狭窄问题以及改善通畅率。

JCEM:度拉糖肽对老年患者疗效和安全性分析

度拉糖肽对≥65岁和<65岁的患者具类似的疗效和安全性。

Prostate Cancer:纳米体多烯紫杉醇脂悬液在转移去势抵抗性前列腺癌中的多中心、回顾性疗效和安全性研究

最近,有研究人员评估了纳米多烯紫杉醇脂悬液(NDLS,DoceAqualip)在转移去势抵抗性前列腺癌(mCRPC)患者中的疗效和安全性。

Ann Rheum Dis:使用乌帕替尼治疗类风湿性关节炎的安全性

乌帕替尼是一种Janus激酶抑制剂,这项研究分析了治疗中重度类风湿关节炎(RA)时乌帕替尼的安全性。